About Us

Jenesis Biosciences works with leading academic centers such as Joslin Diabetes Center and emerging companies in diabetes-related technologies to accelerate the development of new ventures.

The Company is exploring novel technologies in molecular targets for treatment of diabetes complications, biomarkers for risk of disease and response to treatments in diabetes, and beta cell markers of growth and maturation. Jenesis will continue to build a portfolio of approaches based on scientific and clinical innovation and advance their development with academic and industry partners.

Jenesis has appointed a strong Advisory Board of executives and healthcare professionals with senior management experience. The Business Advisory Board members are committed to the venture ideas and programs of the Company, to the continued role of Joslin Diabetes Center’s collaboration with Jenesis, and to making an impact on treatment and prevention of diabetes and its complications.